Treats clinically important hypotension occurring in the setting of anesthesia. ANDA 209784, held by Sandoz. Ephedrine Sulfate.
As of Nov 16, 2026, ANDA 209784 (Ephedrine Sulfate), held by Sandoz, was first approved by FDA on Aug 23, 2017, with 2 approved supplements and 0 published complete response letters.
Ephedrine sulfate injection is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 23, 2017 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Ephedrine Sulfate50MG/ML (50MG/ML) · solution;intravenous | Ephedrine Sulfate | Rx |
| Nov 24, 2020 | Supplement 2Labeling · Standard review | Approved | None posted |
| Oct 28, 2019 | Supplement 1Labeling · Standard review | Approved | None posted |
| Aug 23, 2017 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters